Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)-Reference-Cited by-同舟云学术

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Published:2020-09-01 Issue:9 Volume:5 Page:1036
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Mercuro Nicholas J.¹,Yen Christina F.²,Shim David J.³,Maher Timothy R.⁴,McCoy Christopher M.¹,Zimetbaum Peter J.³⁴,Gold Howard S.²

Affiliation:

1. Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts

2. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

3. Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

4. Harvard-Thorndike Electrophysiology Institute, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2765631/jamacardiology_mercuro_2020_br_200007_1599683695.70852.pdf

Reference15 articles.

1. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].;Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia;Zhonghua Jie He He Hu Xi Za Zhi,2020

2. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.;Wang;Cell Res,2020

3. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.;Gautret;Int J Antimicrob Agents,2020

4. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.;Molina;Med Mal Infect,2020

5. Azithromycin and the risk of cardiovascular death.;Ray;N Engl J Med,2012

Cited by 555 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposed Drugs during the Outbreak of Pandemic COVID-19: A Mini-Review on Their Molecular Structures and Hit-and-Trial Results;ACS Omega;2024-08-20

2. The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters;Medicine;2024-08-09

3. Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality?;World Journal of Virology;2024-06-25

4. Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model;Cardiovascular Toxicology;2024-06-08

5. Impact of Coronavirus Disease 2019 Pandemic on Cardiac Arrest and Emergency Care;Cardiology Clinics;2024-05